EXEL vs TARS
Exelixis vs Tarsus Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
| Metric | EXEL | TARS |
|---|
| AI Score |
67
|
63
|
| Price |
$51.30
|
$69.50
|
| P/E Ratio |
15.60×
|
-63.72×
|
| ROE |
36.2%
|
-19.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
90.6%
|
| Debt / Equity |
0.09×
|
0.26×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
80.7
|
| Beta |
0.422
|
0.512
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TARS.
EXEL leads by 4 points.
EXEL scores 67/100 (Buy) versus TARS at 63/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical